



Curriculum Vitae

Reinhard Büttner

Name Buettner, Reinhard, M.D.
Status Professor and Chairman
Address Institute of Pathology
University Hospital Cologne
Kerpener Strasse 62
D-50937 Cologne/Germany
Phone: 0049-221-478-6320
Fax: 0049-221-478-6360
e-mail: Reinhard.Buettner@uk-koeln.de

Date of birth Jan-15-1960

Nationality German

Professional and Research Experience

1979 - 1986 Lureate of the German National Scholarship Foundation, Studies in Medicine and Anthropology in Mainz, Munich (LMU), London (Middlesex) and Cologne
1987 - 1990 Postdoctoral research fellow Gene Center Munich and MD Anderson Cancer Center, Houston (TX), DFG Fellowship
1999 - 2001 Full Professor for Pathology (C3), RWTH Aachen
2001 - 2011 Professor and Chairman for Pathology, University of Bonn
since 2011 Professor and Chairman for Pathology, University of Cologne

Research focus Molecular Pathology

Awards and honors

2007 - 2009 Dean of the Medical Faculty, University of Bonn Germany
Since 2007 Speaker of the German Collaborative Research Group KoSAR – Sarcoma Research
Since 2009 Executive Board Member, Mildred Scheel Foundation for Cancer Research
2010 Initiation of the Network Genomic Medicine, together with Jürgen Wolf and Roman Thomas
2010 - 2012 President of the German Division, International Academy of Pathology
Since 2015 Executive Board Director, Vladimir Totovic Foundation, German Pathology
2016 Co-President of the Joint IAP/ESP Pathology World Congress 2016, Cologne
2015 Grand Round 480, Johns Hopkins University, Baltimore
2016 Innovation Prize NRW for the Network Genomic Medicine
2015 - 2017 Short Course “Biomarkers” at USCAP

Most important original publications

1. Metzger, E., M. Wissmann, N. Yin, J.M. Müller, R. Schneider, A.H. Peters, T. Gunther, **R. Buettner** and R. Schuele. LSD1 demethylates repressive histone marks to promote androgen receptor-dependent transcription. **Nature** **437**: 436-9 (2005).
2. Metzger, E., A. Imhof, P. Kahl, D. Patel, K. Hoffmeyer, C. Beisenherz-Huss, **R. Buettner**, R. Schüle. Phosphorylation of histone H3 at threonine 6 by protein kinase C β I sets a novel chromatin mark controlling demethylation of histone H3 at K4. **Nature** **464**: 792-6 (2010).
3. Peifer P, Fernández-Cuesta L, et al.... Hallek M, Meyerson M, **Büttner R**, Wolf J, Perner S, Heukamp L, Nürnberg P, Haas S, Thomas RK. Small cell lung cancer: identification of relevant mutated genes in a highly mutated genome by integrative genome analyses, **Nat Genetics**, **44**(10):1104-10 (2012).
4. Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, Pattyn F, Mestdagh P, Menten B, Kuhfittig-Kulle S, Künkel A, König K, Meder L, Chatterjee S, Ullrich RT, Schulte S, Vandesompele J, Speleman F, **Büttner R**, Eggert A, Schulte JH. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. **Science Transl Medicine**, **4**(141):141 ra91. (2012)
5. **Buettner, R.**, J. Wolf, R.K. Thomas. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. **J Clin Oncol.** **31**: 1858-65 (2013).
6. Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, **Buettner R**, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. **Nat Medicine.** 2014 Sep;**20**(9):1027-34.
7. Kloth M, V Ruesseler, C Engel, K Koenig, M Peifer, E Mariotti, H Kuenstlinger, A Florin, C Wodtke, S Holzapfel, S Aretz, P Propping, M Loeffler, M Odenthal, S Merkelbach-Bruse, N Friedrichs, LC Heukamp, T Zander, **R Buettner**. Activating Mutations in ERBB2/HER2 define Vulnerability to pan-HER Inhibitors in Lynch and Lynch-Like Colorectal Cancer. **Gut**, 2015 April 28
8. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Gloeckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortman M, **Büttner R**, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F, Thomas RK, Fischer M. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. **Nature**, 2015 Oct 29;526.

9. George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castañós-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, **Büttner R**, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK. Comprehensive genomic profiles of small cell lung cancer. **Nature**, 2015 Aug 6;524:47-53.
10. Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, **Büttner R**, Thomas RK, Reinhardt HC. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. *Cell*. 2015 Jul 2;162(1):146-59. doi: 10.1016/j.cell.2015.05.053. Erratum in: **Cell**, 2015 Aug 27;162.